8-K
filed November 7, 2024, 6:59 PM ET
ticker ALLO
CIK 0001737287
earnings
confidence high
sentiment neutral
materiality 0.55
Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026
Allogene Therapeutics, Inc.
2024-Q3 EPS reported
-$1.04
revenue$22,000
- Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.
- Ended Q3 with $403.4M cash; maintains 2024 cash burn ~$200M and runway into 2H 2026.
- Pivotal ALPHA3 cema-cel trial in 1L LBCL: ~30 sites active; enrollment completion expected 1H 2026; BLA submission targeted 2027.
- ALLO-329 (CD19/CD70 dual CAR) for autoimmune disease: IND planned Q1 2025, proof-of-concept by YE 2025.
- ALLO-316 for RCC received RMAT designation; Phase 1 TRAVERSE showed 50% ORR in CD70 TPS ≥50% patients.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001737287-24-000072
- form_type
- 8-K
- ticker
- ALLO
- cik
- 0001737287
- company_name
- Allogene Therapeutics, Inc.
- filed_at
- 2024-11-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:09.408992+00:00
- generated_at
- 2026-05-30T03:40:13.903530+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.55
- calibrated_materiality_score
- 0.55
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001737287-24-000072
- json_url
- https://secwatch.observer/filing/0001737287-24-000072.json
- markdown_url
- https://secwatch.observer/filing/0001737287-24-000072.md
- text_url
- https://secwatch.observer/filing/0001737287-24-000072.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1737287/000173728724000072/0001737287-24-000072-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1737287/000173728724000072/allo-20241107.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PKE
Park Aerospace Q4 sales up 43% to $24.2M; EPS $0.19 vs $0.06 YoY; full-year net earnings double to $11.3M
PARK AEROSPACE CORP
May 28, 2026, 4:29 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
GAP
Gap Inc. Q1 net sales up 1% to $3.5B; adj. EPS $0.38; raises full-year EPS outlook
GAP INC
May 28, 2026, 4:16 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PD
PagerDuty Q1 revenue $121M up 1% YoY; new CEO DiLullo; $100M buyback
PagerDuty, Inc.
May 28, 2026, 4:07 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
RICK
RCI Hospitality posts Q2 GAAP loss of $0.04 on $7.6M impairment; non-GAAP EPS rises to $0.78
RCI HOSPITALITY HOLDINGS, INC.
May 28, 2026, 4:07 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
NTAP
NetApp reports Q4/FY2026 results (details not in filing) and adds $1B buyback
NetApp, Inc.
May 28, 2026, 4:05 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.